Iranian Journal of Neurology 2018. 17(1):11-17.

Effectiveness and safety of omega-3 fatty acids for the prevention of ischemic complications following carotid artery stenting: An early terminated pilot study
Farzaneh Foroughinia, Elaheh Jamshidi, Haniyeh Javanmardi, Anahid Safari, Afshin Borhani-Haghighi


Background: We aimed to study the possible beneficial effects of omega-3 polyunsaturated fatty acids (PUFAs) in carotid artery stenting (CAS) procedure for decreasing post-procedural ischemic complications. Although previous evidence demonstrated that omega-3 PUFAs, present in fish oil, can significantly enhance platelet response to antiplatelet agents after percutaneous coronary intervention (PCI), it is unknown whether they can be used in patients undergoing CAS.

Methods: The single-blind, case-control, pilot randomized trial study was planned to perform on 60 patients undergoing CAS (30 in case and 30 in control group). Patients in both groups were pretreated with dual antiplatelet therapy (aspirin 80 mg/day with a loading dose of 325 mg, and clopidogrel 75 mg/day after a loading dose of 600 mg) at least 48 hours before the CAS. 30 patients randomly received
3000 mg loading dose of omega-3 fatty acids
12 hours before the procedure and 1000 mg omega-3 capsule the day after the procedure. All subjects were planned to be visited by neurologist for any peri- and post-procedural complications immediately after the procedure and on first, seventh, and thirtieth days.

Results: We ended the study after the enrollment of 18 patients because of an unexpected hemorrhagic transformation in case group. Two patients in this group developed hemorrhagic symptoms less than 12 hours after the procedure. One of the failures occurred in a patient with small vessel disease. Except these two cases, no one showed any neurological deficit symptoms in both groups.

Conclusion: In patients already receiving dual antiplatelet treatment before CAS, adding omega-3 PUFAs would increase the incidence of hemorrhagic transformation.


Stroke; Intracranial Hemorrhages; Carotid Stenosis; Angioplasty; Stent; Omega-3 Fatty Acids; Platelet Aggregation Inhibitors

Full Text:



Borhani-Haghighi A, Safari R, Heydari ST, Soleimani F, Sharifian M, Yektaparast Kashkuli S, et al. Hospital mortality associated with stroke in southern Iran. Iran J Med Sci 2013; 38(4): 314-20.

Borhani-Haghighi A, Emami M, Vasaksi AS, Shariat A, Banihashemi MA, Nikseresht A, et al. Large-vessel stenosis in the patients with ischemic stroke in Iran: Prevalence, pattern, and risk factors. J Vasc Interv Neurol 2015; 8(1): 11-6.

Borhani Haghighi A, Yousefi S, Bahramali E, Kokabi S, Heydari ST, Shariat A, et al. Demographic and technical risk factors of 30-day stroke, myocardial infarction, and/or death in standard-and high-risk patients who underwent carotid angioplasty and stenting. Interv Neurol 2015; 3(3-4): 165-73.

Borhani Haghighi A, Kokabi S, Yousefi S, Emami M, Shariat A, Nikseresht A, et al. The prevalence and factors contributing to hemodynamic depression in patients undergoing carotid angioplasty and stenting. J Vasc Interv Neurol 2015; 8(4): 5-10.

Divani AA, Zantek ND, Borhani-Haghighi A, Rao GH. Antiplatelet therapy: Aspirin resistance and all that jazz! Clin Appl Thromb Hemost 2013; 19(1): 5-18.

Foroughinia F, Salamzadeh J, Namazi MH. Protection from procedural myocardial injury by omega-3 polyunsaturated fatty acids (PUFAs): Is related with lower levels of creatine kinase-MB (CK-MB) and troponin I? Cardiovasc Ther 2013; 31(5): 268-73.

Mozaffarian D, Wu JH. (n-3) fatty acids and cardiovascular health: Are effects of EPA and DHA shared or complementary? J Nutr 2012; 142(3): 614S-25S.

Lu L, Yang PY, Rui YC, Kang H, Zhang J, Zhang JP, et al. Comparative proteome analysis of rat brain and coronary microvascular endothelial cells. Physiol Res 2007; 56(2): 159-68.

Cottin SC, Sanders TA, Hall WL. The differential effects of EPA and DHA on cardiovascular risk factors. Proc Nutr Soc 2011; 70(2): 215-31.

Iso H, Rexrode KM, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, et al. Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA 2001; 285(3): 304-12.

Zhang W, Hu X, Yang W, Gao Y, Chen J. Omega-3 polyunsaturated fatty acid supplementation confers long-term neuroprotection against neonatal hypoxic-ischemic brain injury through anti-inflammatory actions. Stroke 2010; 41(10): 2341-7.

Gillum RF, Mussolino ME, Madans JH. The relationship between fish consumption and stroke incidence. The NHANES I Epidemiologic Follow-up Study (National Health and Nutrition Examination Survey). Arch Intern Med 1996; 156(5): 537-42.

Ferguson GG, Eliasziw M, Barr HW, Clagett GP, Barnes RW, Wallace MC, et al. The North American symptomatic carotid endarterectomy trial: Surgical results in 1415 patients. Stroke 1999; 30(9): 1751-8.

von Schacky C. A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels. Vasc Health Risk Manag 2006; 2(3): 251-62.

Agren JJ, Vaisanen S, Hanninen O, Muller AD, Hornstra G. Hemostatic factors and platelet aggregation after a fish-enriched diet or fish oil or docosahexaenoic acid supplementation. Prostaglandins Leukot Essent Fatty Acids 1997; 57(4-5): 419-21.

Mori TA, Beilin LJ, Burke V, Morris J, Ritchie J. Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 1997; 17(2): 279-86.

Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170(16): 1433-41.

Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM, et al. Triple versus dual antiplatelet therapy after coronary stenting: Impact on stent thrombosis. J Am Coll Cardiol 2005; 46(10): 1833-7.

Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 2010; 121(23): 2575-83.

Yi X, Chi W, Wang C, Zhang B, Lin J. Low-molecular-weight heparin or dual antiplatelet therapy is more effective than aspirin alone in preventing early neurological deterioration and improving the 6-month outcome in ischemic stroke patients. J Clin Neurol 2015; 11(1): 57-65.

Timaran CH, Veith FJ, Rosero EB, Modrall JG, Valentine RJ, Clagett GP. Intracranial hemorrhage after carotid endarterectomy and carotid stenting in the United States in 2005. J Vasc Surg 2009; 49(3): 623-8.

Abou-Chebl A, Yadav JS, Reginelli JP, Bajzer C, Bhatt D, Krieger DW. Intracranial hemorrhage and hyperperfusion syndrome following carotid artery stenting: Risk factors, prevention, and treatment. J Am Coll Cardiol 2004; 43(9): 1596-601.

Khan U, Porteous L, Hassan A, Markus HS. Risk factor profile of cerebral small vessel disease and its subtypes. J Neurol Neurosurg Psychiatry 2007; 78(7): 702-6.

Simpson JE, Hosny O, Wharton SB, Heath PR, Holden H, Fernando MS, et al. Microarray RNA expression analysis of cerebral white matter lesions reveals changes in multiple functional pathways. Stroke 2009; 40(2): 369-75.

Jeon SB, Kwon SU, Cho AH, Yun SC, Kim JS, Kang DW. Rapid appearance of new cerebral microbleeds after acute ischemic stroke. Neurology 2009; 73(20): 1638-44.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.